Radiation and adjuvant drug-loaded liposomes target glioblastoma stem cells and trigger in-situ immune response.
blood–brain barrier
drug-loaded liposomes
glioblastoma stem cell
immunogenic cell death
radiotherapy
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
The radio- and chemo-resistance of glioblastoma stem-like cells (GSCs), together with their innate tumor-initiating aptitude, make this cell population a crucial target for effective therapies. However, targeting GSCs is hardly difficult and complex, due to the presence of the blood-brain barrier (BBB) and the infiltrative nature of GSCs arousing their dispersion within the brain parenchyma. Liposomes (LIPs), surface-decorated with an Apolipoprotein E-modified peptide (mApoE) to enable BBB crossing, were loaded with doxorubicin (DOXO), as paradigm of cytotoxic drug triggering immunogenic cell death (ICD). Patient-derived xenografts (PDXs) obtained by GSC intracranial injection were treated with mApoE-DOXO-LIPs alone or concomitantly with radiation. Our results indicated that mApoE, through the engagement of the low-density lipoprotein receptor (LDLR), promotes mApoE-DOXO-LIPs transcytosis across the BBB and confers target specificity towards GSCs. Irradiation enhanced LDLR expression on both BBB and GSCs, thus further promoting LIP diffusion and specificity. When administered in combination with radiations, mApoE-DOXO-LIPs caused a significant reduction of in vivo tumor growth due to GSC apoptosis. GSC apoptosis prompted microglia/macrophage phagocytic activity, together with the activation of the antigen-presenting machinery crucially required for anti-tumor adaptive immune response. Our results advocate for radiotherapy and adjuvant administration of drug-loaded, mApoE-targeted nanovectors as an effective strategy to deliver cytotoxic molecules to GSCs at the surgical tumor margins, the forefront of glioblastoma (GBM) recurrence, circumventing BBB hurdles. DOXO encapsulation proved in situ immune response activation within GBM microenvironment.
Sections du résumé
BACKGROUND
BACKGROUND
The radio- and chemo-resistance of glioblastoma stem-like cells (GSCs), together with their innate tumor-initiating aptitude, make this cell population a crucial target for effective therapies. However, targeting GSCs is hardly difficult and complex, due to the presence of the blood-brain barrier (BBB) and the infiltrative nature of GSCs arousing their dispersion within the brain parenchyma.
METHODS
METHODS
Liposomes (LIPs), surface-decorated with an Apolipoprotein E-modified peptide (mApoE) to enable BBB crossing, were loaded with doxorubicin (DOXO), as paradigm of cytotoxic drug triggering immunogenic cell death (ICD). Patient-derived xenografts (PDXs) obtained by GSC intracranial injection were treated with mApoE-DOXO-LIPs alone or concomitantly with radiation.
RESULTS
RESULTS
Our results indicated that mApoE, through the engagement of the low-density lipoprotein receptor (LDLR), promotes mApoE-DOXO-LIPs transcytosis across the BBB and confers target specificity towards GSCs. Irradiation enhanced LDLR expression on both BBB and GSCs, thus further promoting LIP diffusion and specificity. When administered in combination with radiations, mApoE-DOXO-LIPs caused a significant reduction of in vivo tumor growth due to GSC apoptosis. GSC apoptosis prompted microglia/macrophage phagocytic activity, together with the activation of the antigen-presenting machinery crucially required for anti-tumor adaptive immune response.
CONCLUSIONS
CONCLUSIONS
Our results advocate for radiotherapy and adjuvant administration of drug-loaded, mApoE-targeted nanovectors as an effective strategy to deliver cytotoxic molecules to GSCs at the surgical tumor margins, the forefront of glioblastoma (GBM) recurrence, circumventing BBB hurdles. DOXO encapsulation proved in situ immune response activation within GBM microenvironment.
Identifiants
pubmed: 34377986
doi: 10.1093/noajnl/vdab076
pii: vdab076
pmc: PMC8349181
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab076Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
PLoS One. 2012;7(3):e32568
pubmed: 22396775
Cell Rep. 2013 Jan 31;3(1):260-73
pubmed: 23333277
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
J Control Release. 2015 Feb 28;200:138-57
pubmed: 25545217
BMC Res Notes. 2018 Feb 21;11(1):148
pubmed: 29467032
Nature. 2017 Sep 14;549(7671):227-232
pubmed: 28854171
J Neurooncol. 2013 Jan;111(1):19-23
pubmed: 23054563
Cancer Cell. 2016 Nov 14;30(5):683-693
pubmed: 27746144
Lab Invest. 2017 May;97(5):498-518
pubmed: 28287634
EMBO Mol Med. 2016 May 02;8(5):550-68
pubmed: 27138567
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):860-6
pubmed: 17011458
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Pharmacol Rev. 2016 Jul;68(3):701-87
pubmed: 27363439
Nat Rev Neurosci. 2014 Jul;15(7):455-65
pubmed: 24946761
Trends Cancer. 2019 Jan;5(1):46-65
pubmed: 30616755
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Drug Discov Today. 2017 Feb;22(2):270-281
pubmed: 27890669
Clin Cancer Res. 2016 Nov 1;22(21):5337-5348
pubmed: 27281560
J Investig Med. 2019 Apr;67(4):715-719
pubmed: 30765502
Front Neurosci. 2019 Jan 11;12:1019
pubmed: 30686985
Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):165-178
pubmed: 10837714
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813267
Neurosurgery. 1992 Jan;30(1):30-4
pubmed: 1738452
Radiat Oncol. 2015 Aug 06;10:164
pubmed: 26245666
Oncogene. 2016 Nov 10;35(45):5819-5825
pubmed: 27041580
Neurochem Res. 2012 Jun;37(6):1192-200
pubmed: 22228201
Nanomedicine. 2016 Jan;12(1):43-52
pubmed: 26410276
Part Fibre Toxicol. 2013 Aug 01;10:36
pubmed: 24059869
Cell Death Differ. 2018 Aug;25(8):1375-1393
pubmed: 29358668
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
Cancer Discov. 2011 Oct;1(5):442-56
pubmed: 22059152
Lancet. 2019 Feb 16;393(10172):615-617
pubmed: 30782332
Cancer Res. 2000 Apr 15;60(8):2300-3
pubmed: 10786698
Nanomedicine. 2011 Oct;7(5):551-9
pubmed: 21658472
J Control Release. 2017 Mar 10;249:103-110
pubmed: 28153761
Traffic. 2018 Jan;19(1):5-18
pubmed: 28985008
ACS Nano. 2016 Feb 23;10(2):2509-20
pubmed: 26745323
Drugs. 2015 Sep;75(14):1601-11
pubmed: 26323338
J Immunol. 2008 Nov 1;181(9):5829-35
pubmed: 18941170
Nanomedicine. 2014 Oct;10(7):1583-90
pubmed: 24333591
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
Adv Exp Med Biol. 2017;1036:65-79
pubmed: 29275465